How the "BRAIN Initiative" Can Help Big Pharma

From the impact of Obamacare to cutting-edge research, biotech buyouts to Big Pharma court battles, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments across the health-care industry, and their implications for long-term investors. In this week's edition, the team talks about Novartis' patent dispute, stocks that have both popped and plummeted, and companies our analysts will be watching in the coming days.

In the following segment, health-care analyst Max Macaluso discusses President Obama's recent announcement of the $100 million "BRAIN Initiative" and how this project can help drugmakers, including Eli Lilly  (NYSE: LLY  ) and Merck, that are developing new treatments for Alzheimer's disease.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.

The relevant video segment can be found between 4:02 and 5:27.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2349491, ~/Articles/ArticleHandler.aspx, 4/23/2014 4:15:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement